Open Access

Genomic organization and single-nucleotide polymorphism map of desmuslin, a novel intermediate filament protein on chromosome 15q26.3

  • Yuji Mizuno1, 2,
  • Annibale A Puca1,
  • Kristine F O'Brien1,
  • Alan H Beggs3 and
  • Louis M Kunkel1Email author
BMC Genetics20012:8

DOI: 10.1186/1471-2156-2-8

Received: 25 April 2001

Accepted: 20 June 2001

Published: 20 June 2001

Abstract

Background

Desmuslin is an α-dystrobrevin-interacting protein expressed primarily in heart and skeletal muscle. The desmuslin protein interacts with and is closely related to desmin, a protein encoded by a locus mutated in some forms of hereditary distal myopathy. As a muscle-specific intermediate filament protein, desmuslin is also a candidate for myopathies of unknown etiology.

Results

The desmuslin gene was localized to chromosome 15q26.3 by electronic screening of the human DNA sequence database. Primer pairs were designed to amplify the 5 exons of the desmuslin gene in 11 overlapping DNA segments. The desmuslin gene was screened for mutations in 71 patients with various forms of myopathy for which there was no known cause. In this analysis, 10 common and 2 rare amino acid altering single-nucleotide polymorphisms were identified, all of which were seen in a control population of individuals thus making these unlikely causes of the phenotype. Interestingly, one of the single-nucleotide polymorphisms found in a patient resulted in a premature stop codon in the first exon. The nonsense mutation was also detected in the patient's unaffected father and one unaffected control; it was detected in 0.44% (2/454) of unrelated chromosomes and is therefore predicted to have a homozygous frequency of 0.002%.

Conclusion

No causative mutations were found in the desmuslin gene. However, the single-nucleotide polymorphisms mapped in this study represent a well-mapped group that can be used for disequilibrium studies of this region of chromosome 15q26.3.

Background

Dystrophin and its associated proteins are thought to be involved in the anchoring of the muscle cell membrane to the extracellular matrix [1], and the absence of many of these proteins can lead to the phenotype of muscular dystrophy [2]. The dystrophin-associated protein complex (DAPC) consists of several subgroups of protein complexes, each associated either directly or indirectly with dystrophin. The sarcoglycans are four transmembrane proteins [3] that are organized by a fifth protein called sarcospan [4]. This complex is thought to be involved in signalling at the cell membrane [5]. A second subcomplex, known as the dystroglycan complex [6], interacts directly with dystrophin in the cytoplasm and laminin in the extracellular matrix, thus providing a structural link between the inside and the outside of the cell. A third subcomplex involves the dystrobrevins [7, 8] and syntrophins [9] which form a complex at the C-terminal region of dystrophin [10,11,12] and have an as yet unidentified function.

Desmuslin (DMN) was recently identified as an α-dystrobrevin-interacting protein via the yeast two-hybrid method [13]. Both desmuslin mRNA and protein are expressed primarily in cardiac and skeletal muscle and the gene encodes a novel intermediate filament (IF) protein of 1253 amino acids. Electron microscopic analysis shows that desmuslin colocalizes with desmin, another muscle IF protein. Co-immunopreciptation experiments revealed that the desmuslin and α-dystrobrevin interaction involves the region of protein encoded by exons 8-16 of α-dystrobrevin and domains 1A through 2A of the desmuslin rod domain. Desmuslin is hypothesized to function as a mechanical support to the muscle myofibers by making a previously unrecognized linkage between the extracellular matrix via the DAPC and the Z-discs through desmin and plectin [14].

As several IF proteins, including desmin, have been implicated in human genetic disorders such as dominant and recessive congenital and adult onset myopathies [15,16,17,18], desmuslin becomes a candidate to be involved in myopathies as well. Supporting this is the exclusive expression of DMN in skeletal and cardiac muscle. The DMN gene was analyzed for mutations in 71 patients with various forms of muscular dystrophy and myopathy. In addition to 9 single-nucleotide polymorphisms (SNPs) that do not change the protein sequence, we identified 12 SNPs that do alter the residue they encode. Although examination of controls has shown that none of them is likely to cause the phenotype, our results are useful for future disequilibrium studies of this region of chromosome 15q26.3 and for mutation analysis and association studies in other genetic disorders.

Results and Discussion

Using the DMN cDNA sequence (AF359284) as a query to blast the public human genome database, we found a genomic clone (AC018999) that included the entire desmuslin coding sequence. The alignment identified 5 exons which are schematically indicated in Figure 1. Eleven sets of primer pairs were developed to amplify the 5 exons and the flanking intron sequences (Table 1). The primers were designed to amplify overlapping segments of the desmuslin coding sequence as indicated in Figure 1.
https://static-content.springer.com/image/art%3A10.1186%2F1471-2156-2-8/MediaObjects/12863_2001_Article_12_Fig1_HTML.jpg
Figure 1

Schematic representation of the desmuslin gene and protein. Desmuslin protein structure, genomic organization, approximate location of SNPs identified in this study and primer pairs used to amplify the entire coding sequence are indicated. A comparison of the DMN cDNA sequence with its related genomic DNA led to the identification of 5 exons ranging from 71 bp (exon 3) to 2447 bp (exon 4). The exact start of transcription in exon 1 and the termination of transcription at the end of exon 5 are unknown. Unlike the brain DMN cDNA, muscle DMN cDNA does not contain the sequence between exons 4 and 5 (indicated by an open box). The locations of the 21 SNPs are indicated by arrows; the 12 SNPs that alter an amino acid codon are shown in red and the 9 silent SNPs are shown in black. The exact position of each of the SNPs is described in Table 3. The positions of the 11 primer pairs are also shown below the respective exons.

Table 1

Eleven PCR primer sets that allow the amplification of the entire coding sequence and surrounding intronic sequence of the DMN gene.

Primer

Primer Sequence

1F

5' - ATCCACCAAGGCCAGGACACTCGTATGCTCC

1R

5' - TCGTCCTCGTACAGCTGCAC

2F

5' - GGAGAGGACGAGACCGGGACAAGACCA

2R

5' - CGGAAATGCATGGTAAGGCTG

3F

5' - GAGCTGCAGCGCCTGGATGCGGAGGAG

3R

5' - GTTAAAGCAGCTGCCACCTAACCCCATGACGAGGA

4F

5' - GGAAACCATCCTGCAAGTGACTGCATG

4R

5' - GAGACACCTGCTCAGTGACCTAAGC

5F

5' - GGTGACACTATGGTCATTGGCCGCATACCAC

5R

5' - CCAGGGGTGTGAAACACAAGTTCAGGTGCAC

6F

5' - CACAAAAACGAGCACCTCTGACCTCTCTGGG

6R

5' - GAATGACGGTCCTCTCATTTGACCG

7F

5' - CCAACGTCAGAACTTTCTCTCCAACC

7R

5' - CCAGGCCAGCTTCATCGGAAACATC

8F

5' - GTCACTTACGTGGACAGGAAAGAGC

8R

5' - GACTGTGGGTTCGGCATGAAATTC

9F

5' - GGGCGAGCAGAGTTATTTTGTGTCC

9R

5' - CTCCATCTCACTGGCCTCATCTTTGC

10F

5' - GAGCGTTTCCGTGGATGTCAAGAAG

10R

5' - GATGACTTCTCTGGACAGTGGACTTTGACCGG

11F

5' - GAGCGTTTCCGTGGATGTCAAGAAG

11R

5' - GTTAAGGCCTTTGGATGTTGGCACG

Desmin, a desmuslin-interacting protein, has been implicated in hereditary distal myopathies implying that desmuslin itself may also be involved in myopathies of unknown etiology. DNA samples isolated from 71 dystrophic and myopathic patients (as described in Table 2) were analyzed by direct sequencing to determine whether the phenotype was the result of a desmuslin mutation. All observed variants were subsequently tested in ≤ 156 control individuals. These analyses revealed 10 common and 2 rare SNPs [19, 20] that alter an amino acid codon; 7 result in non-conservative amino acids changes (Table 3).
Table 2

Summary of clinical diagnoses and pathological findings of patient samples studied for alterations in DMN.

Clinical Diagnosis

Description

# of samples

Congenital Myopathy

Nemaline Myopathy

50

 

Multicore/minicore Disease

6

 

Myotubular Myopathy

2

 

Spheroid Body Myopathy

1

 

Desmuslin accumulation

2

 

Undefined

2

Muscular Dystrophy

Limb-Girdle MD

4

 

Undefined

4

Table 3

Summary of SNPs in theDMN gene.

   

Nucleotide

Nucleotide

Amino Acid

  

# of chromosomes

SNP

Exon

Domain

Position

Change

Position

 

Amino Acid Change

Total

%

1

1

Rod

408

CGG

136

 

none

91

64.1

    

CGA

   

51

35.9

2

1

Rod

457

A GG

153

 

none

91

64.1

    

C GG

   

51

35.9

3

1

Rod

598

C AG

200

Gln

non-conservative

452

99.6

    

T AG

 

STOP

 

2

0.4

4

2

Rod

815

GC G

272

Ala

conservative

103

57.9

    

GT G

 

Val

 

75

42.1

5

3

C-terminal

988

G TT

330

Val

conservative

165

90.7

    

A TT

 

Ile

 

17

9.3

6

4

C-terminal

1063

A GG

335

Arg

non-conservative

79

87.8

    

T GG

 

Trp

 

11

12.2

7

4

C-terminal

1596

TCC

532

 

none

128

91.4

    

TCT

   

12

8.6

8

4

C-terminal

1700

CC G

567

Pro

conservative

149

81.9

    

CT G

 

Leu

 

33

18.1

9

4

C-terminal

1713

AGC

571

 

none

162

89.0

    

AGT

   

20

11.0

10

4

C-terminal

1835

GA A

612

Glu

non-conservative

180

97.8

    

GC A

 

Ala

 

4

2.2

11

4

C-terminal

1953

ACT

651

 

none

131

72.8

    

ACC

   

49

27.2

12

4

C-terminal

2010

TAC

670

 

none

176

97.8

    

TAT

   

4

2.2

13

4

C-terminal

2282

CC G

761

Pro

conservative

114

91.9

    

CT G

 

Leu

 

10

8.1

14

4

C-terminal

2424

CCC

808

 

none

63

75.0

    

CCT

   

21

25.0

15

4

C-terminal

2836

C GG

946

Arg

non-conservative

324

99.4

    

T GG

 

Trp

 

2

0.6

16

4

C-terminal

2927

CA G

976

Gln

non-conservative

187

98.4

    

CG G

 

Arg

 

3

1.6

17

4

C-terminal

2937

CCG

979

 

none

187

99.5

    

CCA

   

1

0.5

18

4

C-terminal

3176

CC G

1059

Pro

conservative

126

98.4

    

CT G

 

Leu

 

2

1.6

19

4

C-terminal

3195

TTC

1065

 

none

95

76.6

    

TTT

   

29

23.4

20

4

C-terminal

3200

CG T

1067

Arg

non-conservative

114

91.9

    

CC T

 

Pro

 

10

8.1

21

4

C-terminal

3230

TC A

1077

Ser

non-conservative

115

89.8

    

TT A

 

Leu

 

13

10.2

The details of 21 SNPs are shown. The exon and domain location as well as the nucleotide and amino acid positions of SNP are given. Also listed are the major and minor alleles, both as nucleotide and amino acid, and the corresponding frequencies, in terms of numbers of chromosomes and percentage. The nucleotide substitution is highlighted in bold. The amino acid change indicates the degree of alteration in the encoded residue; the change is described as none if there was no change, conservative if the alteration does not change the residue's polarity or charge, and non-conservative if the polarity and/or charge of the encoded residues differ.

None of the SNPs seem associated with the patient phenotypes as each was also found in the control population. Nine silent SNPs, which did not alter an amino acid, were also identified in the patient population; several of these SNPs showed a high degree of heterozygosity. Most were tested for and detected in the control population, thus making desmuslin an unlikely candidate to be involved in these myopathies, but this first pass can be followed by others in a larger set of patient samples.

Interestingly, SNP 3, a C598T substitution resulting in a premature stop codon in exon 1, was detected in a single Nemaline myopathy patient. Neither the proband's mother nor any of the other patients was found to carry this mutation (Figure 2A). The C598T mutation removed a Pvu II site, thus permitting detection of the alteration by restriction digest analysis of a PCR product generated from genomic DNA. The assay is outlined schematically in Figure 2B and documented in Figure 2C. Using this Pvu II assay, the C598T change was detected in the unaffected father of the patient, making it unlikely that heterozygosity for the C598T change is the causative mutation in the myopathic proband.
https://static-content.springer.com/image/art%3A10.1186%2F1471-2156-2-8/MediaObjects/12863_2001_Article_12_Fig2_HTML.jpg
Figure 2

Analysis of SNP3 (C598T) in patient and control samples. (A) Sequence results of the C598T patient and his mother. At nucleotide number 598, the patient has a C and T, indicated by N. The patient's unaffected mother is homozygous for C. (B) Pvu II site amplified with 3F and 3R. The size of PCR product amplified with 3F and 3R is 790 bp and contains three Pvu II restriction sites. When the PCR product from a control subject is digested with Pvu II, four products of 321 bp, two of 138 bp and two of 10 bp are generated. Since the C598T removes the first Pvu II restriction site, digestion of the amplification product will produce a fragment of 459 bp instead of 321 bp and 138 bp. (C) Electrophoresis of PCR product digested with Pvu II shows that the patient and his unaffected father both have a band of 459 bp. The 138 bp fragment in the mother and control is twice as strong as those of the patient and the father. Similarly the 321 bp band in the mother and control is stronger than in the patient and his father.

The removal of the Pvu II site allowed rapid screening of additional patients and control samples by DNA amplification of the region and subsequent digestion of the PCR product with Pvu II. One of 312 control chromosomes was found to have lost the Pvu II site, and the heterozygous presence of the C598T mutation was confirmed by DNA sequencing of the PCR product. Thus it is likely that the C598T mutation is not responsible for the myopathic phenotype of the proband. This is a surprising result considering that a single copy of this stop codon is present in 0.44% (2/454) of the population and 0.002% of the population is predicted to carry this nonsense mutation in a homozygous state. The phenotype of the latter individuals is not known.

There is the possibility that either the heterozygous C598T DMN mutation combined with another mutation in a different gene or the C598T in a homozygous state causes muscular dystrophy or myopathy of unknown genetic pathogenesis. The C598T DMN mutation is a good candidate to be a modifier for muscular and/or cardiac phenotypes, considering: (i) the frequency of the mutation in the normal population in the heterozygous as well as homozygous state; and (ii) the key role of desmuslin in connecting the Z-discs to the extracellular matrix. The desmuslin SNPs should be examined in a larger set of myopathy and muscular dystrophy patients to test this hypothesis. More specifically, it should be determined whether there is a statistically significant difference in the frequency of individual or clustered SNP haplotypes between the patient and the control populations.

The desmuslin coding sequence is highly polymorphic with 9 SNPs that do not alter an amino acid and 12 that do. Ten of these variations have minor allele frequencies that are represented in over 10% of the chromosomes sampled. These 10 are spaced within a genomic interval of ≤ 28 kilobases, or approximately 1 per 2800 bases. These highly informative markers are thus very useful for genetic analysis. The presence of so many SNPs within the coding sequence of a protein is somewhat unexpected and is much greater than that documented for other genes. This degree of variability may reflect a redundancy of desmuslin at the Z-line where other IF proteins with potentially overlapping functions are located [21].

Conclusions

The characterization of the individual components that form protein complexes in skeletal muscle and heart, especially information concerning genotype-phenotype correlations, will increase our understanding of the pathophysiology of human muscle diseases. We encourage other groups to test for the presence of the C598T DMN mutation in their human patient samples affected by muscular and cardiac diseases. The generation of desmuslin null animal models will also contribute to the understanding of the role of this protein in muscle and cardiac disease.

Materials and Methods

Blood samples were obtained from patients and control subjects under IRB-approved informed consent. The genomic DNA extracted from these blood samples was used as the template for the PCR assay. Using an Advantage-GC cDNA PCR polymerase (Clontech) and Pfu DNA polymerase (Stratagene), PCR was carried out with primers specific to the exon and/or intron of DMN sequence (Table 1) under the following conditions: 94°C for 1 min followed by 35 cycles of 94°C for 1 min, 57-59 °C for 1 min, 72°C for 3 min and a final extension time of 10 min at 72°C. The amplification products were purified using the QIAGEN PCR purification kit and analyzed on either an ABI 373 or 377 automated sequencer with fluorescent dye terminator chemistry (Applied Biosystems).

The PCR products were also digested with Pvu II and Msp I in order to screen for the C598T and C2836T SNPs, respectively.

Abbreviations

DAPC: 

Dystrophin-associated protein complex

DMN: 

Desmuslin, SNP: Single-nucleotide polymorphism

IF: 

Intermediate filament

Declarations

Acknowledgments

The authors would like to thank Corinne Strickland for assistance in identifying appropriate patient samples and the members of the Children's Hospital - Genetics Department Sequencing Facility which is supported by an MRRC Grant (NIH-P30-HD18655. AHB is supported by the Muscular Dystrophy Association of the USA, the Joshua Frase Foundation and grants AR44345, and AR02026 from the NIAMS of NIH. YM, AAP and LMK are supported by the Howard Hughes Medical Institute. LMK is an investigator of the Howard Hughes Medical Institute.

Authors’ Affiliations

(1)
Howard Hughes Medical Institute, Children's Hospital and Harvard Medical School
(2)
Department of Neurology, Gunma University School of Medicine
(3)
Division of Genetics, Children's Hospital and Harvard Medical School

References

  1. Yoshida M, Suzuki A, Yamamoto H, Noguchi S, Mizuno Y, Ozawa E: Dissociation of the complex of dystrophin and its associated proteins into several unique groups by n-octyl beta-D-glucoside. Eur J Biochem. 1994, 222: 1055-1061.View ArticlePubMedGoogle Scholar
  2. Ozawa E, Nishino I, Nonaka I: Sarcolemmopathy: Muscular Dystrophies with Cell Membrane Defects. Brain Pathol. 2001, 11: 218-230.View ArticlePubMedGoogle Scholar
  3. Ozawa E, Noguchi S, Mizuno Y, Hagiwara Y, Yoshida M: Invited review: From dystrophinopathy to sarcoglycanopathy: Evolution of a concept of muscular dystrophy. Muscle Nerve. 1998, 21: 421-438. 10.1002/(SICI)1097-4598(199804)21:4<421::AID-MUS1>3.3.CO;2-W.View ArticlePubMedGoogle Scholar
  4. Crosbie RH, Heighway J, Venzke DP, Lee JC, Campbell KP: Sarcospan, the 25-kDa transmembrane component of the dystrophin-glycoprote in complex. J Biol Chem. 1997, 272: 31221-31224. 10.1074/jbc.272.50.31221.View ArticlePubMedGoogle Scholar
  5. Thompson TG, Chan YM, Hack AA, Brosius M, Rajala M, Lidov HG, McNally EM, Watkins S, Kunkel LM: Filamin 2 (FLN2): A muscle-specific sarcoglycan interacting protein. J Cell Biol. 2000, 148: 115-126. 10.1083/jcb.148.1.115.PubMed CentralView ArticlePubMedGoogle Scholar
  6. Ibraghimov-Beskrovnaya O, Ervasti JM, Leveille CJ, Slaughter CA, Sernett SW, Campbell KP: Primary structure of dystrophin-associated glycoproteins linking dystrophin to the extracellular matrix. Nature. 1992, 355: 696-702. 10.1038/355696a0.View ArticlePubMedGoogle Scholar
  7. Sadoulet-Puccio HM, Khurana TS, Cohen JB, Kunkel LM: Cloning and characterization of the human homologue of a dystrophin related phosphoprotein found at the Torpedo electric organ post-synaptic membrane. Hum Mol Genet. 1996, 5: 489-496. 10.1093/hmg/5.4.489.View ArticlePubMedGoogle Scholar
  8. Sadoulet-Puccio HM, Kunkel LM: Dystrophin and its isoforms. Brain Pathol. 1996, 6: 25-35.View ArticlePubMedGoogle Scholar
  9. Ahn AH, Feener CA, Gussoni E, Yoshida M, Ozawa E, Kunkel LM: The three human syntrophin genes are expressed in diverse tissues, have distinct chromosomal location and each bind to dystrophin and its relatives. J Biol Chem. 1996, 271: 2724-2730. 10.1074/jbc.271.30.18100.View ArticlePubMedGoogle Scholar
  10. Ahn A, Kunkel L: Syntrophin binds to an alternatively spliced exon of dystrophin. J Cell Biol. 1995, 128: 363-371.View ArticlePubMedGoogle Scholar
  11. Sadoulet-Puccio HM, Rajala M, Kunkel LM: Dystrobrevin and dystrophin: An interaction through coiled-coil motifs. Proc Natl Acad Sci U S A. 1997, 94: 12413-12418. 10.1073/pnas.94.23.12413.PubMed CentralView ArticlePubMedGoogle Scholar
  12. Suzuki A, Yoshida M, Ozawa E: Mammalian alpha 1- and beta 1-syntrophin bind to the alternative splice- prone region of the dystrophin COOH terminus. J Cell Biol. 1995, 128: 373-381.View ArticlePubMedGoogle Scholar
  13. Mizuno Y, Thompson TG, Guyon JR, Lidov HG, Brosius M, Imamura M, Ozawa E, Watkins SC, Kunkel LM: Desmuslin, an intermediate filament protein that interacts with alpha - dystrobrevin and desmin. Proc Natl Acad Sci U S A. 2001, 98: 6156-6161. 10.1073/pnas.111153298.PubMed CentralView ArticlePubMedGoogle Scholar
  14. Hijikata T, Murakami T, Imamura M, Fujimaki N, Ishikawa H: Plectin is a linker of intermediate filaments to Z-discs in skeletal muscle fibers. J Cell Sci. 1999, 112: 867-876.PubMedGoogle Scholar
  15. Dalakas MC, Park KY, Semino-Mora C, Lee HS, Sivakumar K, Goldfarb LG: Desmin myopathy, a skeletal myopathy with cardiomyopathy caused by mutations in the desmin gene. N Engl J Med. 2000, 342: 770-780. 10.1056/NEJM200003163421104.View ArticlePubMedGoogle Scholar
  16. Goldfarb LG, Park KY, Cervenakova L, Gorokhova S, Lee HS, Vasconcelos O, Nagle JW, Semino-Mora C, Sivakumar K, Dalakas MC: Missense mutations in desmin associated with familial cardiac and skeletal myopathy. Nat Genet. 1998, 19: 402-403. 10.1038/1300.View ArticlePubMedGoogle Scholar
  17. Munoz-Marmol AM, Strasser G, Isamat M, Coulombe PA, Yang Y, Roca X, Vela E, Mate JL, Coll J, Fernandez-Figueras MT, Navas-Palacios JJ, Ariza A, Fuchs E: A dysfunctional desmin mutation in a patient with severe generalized myopathy. Proc Natl Acad Sci U S A. 1998, 95: 11312-11317. 10.1073/pnas.95.19.11312.PubMed CentralView ArticlePubMedGoogle Scholar
  18. Sjoberg G, Saavedra-Matiz CA, Rosen DR, Wijsman EM, Borg K, Horowitz SH, Sejersen T: A missense mutation in the desmin rod domain is associated with autosomal dominant distal myopathy, and exerts a dominant negative effect on filament formation. Hum Mol Genet. 1999, 8: 2191-2198. 10.1093/hmg/8.12.2191.View ArticlePubMedGoogle Scholar
  19. Cargill M, Altshuler D, Ireland J, Sklar P, Ardlie K, Patil N, Shaw N, Lane CR, Lim EP, Kalyanaraman N, Nemesh J, Ziaugra L, Friedland L, Rolfe A, Warrington J, Lipshutz R, Daley GQ, Lander ES: Characterization of single-nucleotide polymorphisms in coding regions of human genes. Nat Genet. 1999, 22: 231-238. 10.1038/10290.View ArticlePubMedGoogle Scholar
  20. Halushka MK, Fan JB, Bentley K, Hsie L, Shen N, Weder A, Cooper R, Lipshutz R, Chakravarti A: Patterns of single-nucleotide polymorphisms in candidate genes for blood-pressure homeostasis. Nat Genet. 1999, 22: 239-247. 10.1038/10297.View ArticlePubMedGoogle Scholar
  21. North KN, Yang N, Wattanasirichaigoon D, Mills M, Easteal S, Beggs AH: A common nonsense mutation results in alpha-actinin-3 deficiency in the general population. Nat Genet. 1999, 21: 353-354. 10.1038/7675.View ArticlePubMedGoogle Scholar

Copyright

© Mizuno et al; licensee BioMed Central Ltd. 2001

This article is published under license to BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original URL.